Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK11 | Q15759 | 14/20 | 0.77 |
| ▸ | MAPK14 | Q16539 | 14/20 | 0.77 |
| ▸ | ALOX5 | P09917 | 13/20 | 0.77 |
| ▸ | CSNK1A1 | P48729 | 4/20 | 0.77 |
| ▸ | CSNK1D | P48730 | 4/20 | 0.77 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.77 |
| ▸ | CSNK1E | P49674 | 3/20 | 0.77 |
| ▸ | CSNK1A1L | Q8N752 | 3/20 | 0.77 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.77 |
| ▸ | MAPK13 | O15264 | 13/20 | 0.70 |
| ▸ | MAPK12 | P53778 | 13/20 | 0.70 |
| ▸ | GCGR | P47871 | 12/20 | 0.70 |
| ▸ | PRKD3 | O94806 | 3/20 | 0.70 |
| ▸ | MAP4K4 | O95819 | 3/20 | 0.70 |
| ▸ | FRK | P42685 | 3/20 | 0.70 |
| ▸ | MAPK9 | P45984 | 3/20 | 0.70 |
| ▸ | GSK3B | P49841 | 3/20 | 0.70 |
| ▸ | PTK6 | Q13882 | 3/20 | 0.70 |
| ▸ | PRKD2 | Q9BZL6 | 2/20 | 0.70 |
| ▸ | CLK4 | Q9HAZ1 | 2/20 | 0.70 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7243804 | 0.88 | ALOX5 (0.79) | MAPK11MAPK14ALOX5CSNK1A1CSNK1D | |
| SCHEMBL4336547 | 0.87 | MAPK14 (1.00) | MAPK11MAPK14ALOX5CSNK1A1CSNK1D | |
| SCHEMBL9201148 | 0.87 | MAPK14 (1.00) | MAPK11MAPK14ALOX5CSNK1A1CSNK1D | |
| SCHEMBL458366 | 0.87 | MAPK14 (1.00) | MAPK11MAPK14ALOX5CSNK1A1CSNK1D | |
| Hydrochloric Acid SCHEMBL16566835 | 0.86 | MAPK14 (0.98) | MAPK11MAPK14ALOX5CSNK1A1CSNK1D | |
| SCHEMBL4552997 | 0.84 | ALOX5 (1.00) | MAPK11MAPK14ALOX5CSNK1A1CSNK1D | |
| SCHEMBL19868925 | 0.83 | MAPK11 (1.00) | MAPK11MAPK14ALOX5CSNK1A1CSNK1D | |
| SCHEMBL15075603 | 0.83 | MAPK11 (1.00) | MAPK11MAPK14ALOX5CSNK1A1CSNK1D | |
| SCHEMBL7388098 | 0.82 | ALOX5 (0.78) | MAPK11MAPK14ALOX5CSNK1A1CSNK1D | |
| SCHEMBL21169981 | 0.82 | MAPK11 (0.79) | MAPK11MAPK14ALOX5CSNK1A1CSNK1D |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 55 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2675409-A1 | PREVENTION OF AND RECOVERY FROM DRUG-INDUCED OTOTOXICITY | Otonomy, Inc. (US) | 2013-12-25 | — | — | EP | claimed |
| WO-2012112810-A1 | PREVENTION OF AND RECOVERY FROM DRUG-INDUCED OTOTOXICITY | OTONOMY, INC. (US) | 2012-08-23 | — | — | WO | claimed |
| WO-2003099212-A2 | MITOGEN ACTIVATED PROTEIN KINASE INHIBITOR COMPOSITIONS FOR LYMPHOMA THERAPY | THE UNIVERSITY OF UTAH RESEARCH FOUNDATION (US) | 2003-12-04 | — | — | WO | claimed |
| JP-H09500137-A | — | — | 1997-01-07 | — | — | JP | claimed |
| EP-0708768-A4 | TRI-SUBSTITUTED IMIDAZOLES HAVING MULTIPLE THERAPEUTIC PROPERTIES | SMITHKLINE BEECHAM CORP (US) | 1996-08-21 | — | — | EP | claimed |
| EP-0708768-A1 | TRI-SUBSTITUTED IMIDAZOLES HAVING MULTIPLE THERAPEUTIC PROPERTIES | SMITHKLINE BEECHAM CORPORATION (US) | 1996-05-01 | — | — | EP | claimed |
| WO-1995002591-A1 | TRI-SUBSTITUTED IMIDAZOLES HAVING MULTIPLE THERAPEUTIC PROPERTIES | SMITHKLINE BEECHAM CORPORATION (US) | 1995-01-26 | — | — | WO | claimed |
| US-12533425-B2 | Methods and systems using peptides for targeting and mapping human nerves in image guided surgery, diagnostics and therapeutic delivery | ALUME BIOSCIENCES, INC. (US) | 2026-01-27 | — | — | US | disclosed |
| EP-4484952-A2 | OPTIMIZED PEPTIDES FOR TARGETING HUMAN NERVES AND THEIR USE IN IMAGE GUIDED SURGERY, DIAGNOSTICS AND THERAPEUTIC DELIVERY | The Regents of the University of California (US) | 2025-01-01 | — | — | EP | disclosed |
| EP-3661539-B1 | OPTIMIZED PEPTIDES FOR TARGETING HUMAN NERVES AND THEIR USE IN IMAGE GUIDED SURGERY, DIAGNOSTICS AND THERAPEUTIC DELIVERY | UNIV CALIFORNIA (US) | 2024-10-09 | — | — | EP | disclosed |
| US-20240207422-A1 | NERVE TARGETING PEPTIDE CONJUGATES AND METHODS OF USE | ALUME BIOSCIENCES INC (US) | 2024-06-27 | — | — | US | disclosed |
| US-20240207421-A1 | NERVE TARGETING PEPTIDES AND METHODS OF USE | ALUME BIOSCIENCES INC (US) | 2024-06-27 | — | — | US | disclosed |
| US-20240124523-A1 | OPTIMIZED PEPTIDES FOR TARGETING HUMAN NERVES AND THEIR USE IN IMAGE GUIDED SURGERY, DIAGNOSTICS AND THERAPEUTIC DELIVERY | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2024-04-18 | — | — | US | disclosed |
| WO-2010121023-A2 | PEPTIDES AND APTAMERS FOR TARGETING OF NEURON OR NERVES | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2010-10-21 | — | — | WO | disclosed |
| EP-1861715-B1 | BIOLOGICAL MARKERS PREDICTIVE OF ANTI-CANCER RESPONSE TO EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITORS | OSI PHARM INC (US) | 2010-08-11 | — | — | EP | disclosed |
| EP-1861715-A2 | BIOLOGICAL MARKERS PREDICTIVE OF ANTI-CANCER RESPONSE TO EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITORS | OSI Pharmaceuticals, Inc. (US) | 2007-12-05 | — | — | EP | disclosed |
| WO-2006101925-A2 | BIOLOGICAL MARKERS PREDICTIVE OF ANTI-CANCER RESPONSE TO EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITORS | OSI PHARMACEUTICALS, INC. (US) | 2006-09-28 | — | — | WO | disclosed |
| EP-0889726-A4 | NOVEL CYCLOALKYL SUBSTITUTED IMIDAZOLES | SMITHKLINE BEECHAM CORP (US) | 1999-07-21 | — | — | EP | disclosed |
| EP-0889726-A1 | NOVEL CYCLOALKYL SUBSTITUTED IMIDAZOLES | SMITHKLINE BEECHAM CORPORATION (US) | 1999-01-13 | — | — | EP | disclosed |
| WO-1997025048-A1 | NOVEL CYCLOALKYL SUBSTITUTED IMIDAZOLES | SMITHKLINE BEECHAM CORPORATION (US) | 1997-07-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12533425-B2 | Methods and systems using peptides for targeting and mapping human nerves in image guided surgery, diagnostics and therapeutic delivery | NGLY1, VGF, GAP43 | MAPK11 653/4885MAPK14 2042/4885ALOX5 4683/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.